Preliminary results from TRASTYVERE study: A retrospective analysis of heavily pretreated HER2-positive metastatic breast cancer patients treated in Spain with lapatinib plus trastuzumab as compassive therapy

被引：0
|
作者：
Gavila, J. [1 ]
Bermejo, B. [2 ]
Manso, L. [3 ]
Munoz, E. [4 ]
Anton, A. [5 ]
Brunet, J. [6 ]
Rodriguez, C. A. [7 ]
Santaballa, A. [8 ]
Cortes, J. [4 ,9 ]
Llombart, A. [9 ,10 ]
机构：
[1] Inst Valenciano Oncol, Valencia, Spain
[2] Hosp Clin Univ Valencia, Valencia, Spain
[3] Hosp 12 Octubre, Madrid, Spain
[4] VHIO, Barcelona, Spain
[5] Hosp Univ Miguel Servet, Zaragoza, Spain
[6] Inst Catala Oncol Girona, Girona, Spain
[7] Hosp Univ Salamanca IBSAL, Salamanca, Spain
[8] Hosp Univ La Fe Valencia, Valencia, Spain
[9] Med Scientia Innovat Res MedSIR ARO, Oncol, Barcelona, Spain
[10] Hosp Arnau de Vilanova Valencia, Valencia, Spain
来源：
EUROPEAN JOURNAL OF CANCER | 2014年 / 50卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S181 / S181
页数：1
相关论文
共 50 条
  • [11] Efficacy of trastuzumab-based therapy after disease progression on lapatinib based therapy in heavily pretreated HER2-positive metastatic breast cancer patients.
    Uncu, Dogan
    Bayoglu, Ibrahim Vedat
    Arslan, Ulku Yalcintas
    Kucukoner, Mehmet
    Artac, Mehmet
    Koca, Dogan
    Oguz, Arzu
    Demirci, Umut
    Arpaci, Erkan
    Dogan, Mutlu
    Kucukzeybek, Yuksel
    Turker, Ibrahim
    Isikdogan, Abdurrahman
    Guler, Tunc
    Zengin, Nurullah
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [12] Lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single institution experience
    Crivellari, Diana
    Spazzapan, Simon
    Lombardi, Davide
    Militello, Loredana
    Torrisi, Elena
    Russo, Alessia E.
    Sorio, Roberto
    Talamini, Renato
    Miolo, Gianmaria
    Carli, Paolo
    Veronesi, Andrea
    TUMORI JOURNAL, 2012, 98 (01): : 33 - 38
  • [13] Trastuzumab-Emtansine versus Capecitabine plus Lapatinib in Patients with previously treated HER2-positive metastatic Breast Cancer
    Ruckhaeberle, Eugen
    ONKOLOGE, 2017, 23 (11): : 940 - 942
  • [14] A nationwide observational study in heavily pretreated metastatic HER2-positive breast cancer patients
    Due, Asbjorn
    Berg, Tobias
    Jensen, Maj-Britt
    Yammeni, Sophie
    Volmer, Lone
    Brems-Eskildsen, Anne Sofie
    Andersen, Klaus Kaae
    Rana, Saeeda
    Knoop, Ann
    Kuemler, Iben
    ACTA ONCOLOGICA, 2023, 62 (02) : 126 - 133
  • [15] A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+metastatic breast cancer progressing on trastuzumab therapy
    O'Shaughnessy, J.
    Blackwell, K. L.
    Burstein, H.
    Storniolo, A. M.
    Sledge, G.
    Baselga, J.
    Koehler, M.
    Laabs, S.
    Florance, A.
    Roychowdhury, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [16] Pyrotinib plus trastuzumab versus pertuzumab plus trastuzumab in patients with HER2-positive metastatic breast cancer: A multicenter, retrospective study
    Wang, B.
    You, S.
    Xie, Y.
    Xu, F.
    Sang, D.
    Luo, T.
    Yuan, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S361 - S362
  • [17] Retreatment with trastuzumab after progression on lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single-institution experience
    Carli, Paolo
    Militello, Loredana
    Miolo, Gian Maria
    Quitadamo, Daniela
    Lombardi, Davide
    Torrisi, Elena
    Scalone, Simona
    Crivellari, Diana
    Spazzapan, Simon
    TUMORI, 2014, 100 (06) : 605 - 611
  • [18] Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine in Patients With Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Retrospective Study
    Xie, Yizhao
    Li, Yi
    Ting, Luo
    Sang, Die
    Yuan, Peng
    Li, Wei
    Li, Huihui
    Ge, Rui
    Wang, Biyun
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [19] Metronomic cyclophosphamide and capecitabine combined with lapatinib in heavily pretreated metastatic breast cancer (MBC) HER2-positive patients.
    Cagossi, Katia
    Lazzaretti, Maria Grazia
    Ferrari, Alessia
    Razzini, Giorgia
    Leporati, Meri
    Silvestri, Rosangela
    Iadanza, Manlio
    Iop, Aldo
    Artioli, Fabrizio
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [20] Efficacy and safety evaluation of eribulin-trastuzumab combination therapy with heavily pretreated HER2-positive metastatic breast cancer
    Sarici, Furkan
    Altundag, Kadri
    JOURNAL OF BUON, 2020, 25 (06): : 2562 - 2569
12345